Educational use only. Check doses against the product monograph and local protocols.

potassium binders

in review 3 min read Updated 2026-10-27
potassium binders

Non-absorbed GI exchangers that remove K⁺. Their main role is keeping RASi/MRA going in CKD and HF. KDIGO: treat the K⁺ rather than stop renoprotection. SZC acts within about 1 h and is the acute binder of choice (UKKA). Patiromer is slower (4–7 h). SPS/calcium resonium is no longer routine acutely.

mechanism

SZC: crystalline lattice that traps K⁺ (and NH₄⁺) in exchange for Na⁺/H⁺ along the whole GI tract. Patiromer: polymer exchanging Ca²⁺ for K⁺, mainly in the colon. SPS: resin exchanging Na⁺ (calcium resonium: Ca²⁺).


dosing

agentacute (UKKA 2023)chroniconset
SZC (Lokelma)10 g TDS up to 72 h for K⁺ ≥6.5 (1B); consider at 6.0–6.45 g daily → max 10 g daily, or down to 5 g alternate days≈1 h
patiromer (Veltassa)8.4 g daily (≥6.0; 1C)8.4 g daily, titrate4–7 h
calcium resonium (or SPS)not routine (2B)15 g TDS short term, only if newer binders aren’t an option (2C)slow, variable
  • UKKA chronic criteria (for both SZC and patiromer): confirmed K⁺ ≥6.0, CKD G3b–5 not on dialysis or HF, on a suboptimal RASi dose because of K⁺. Stop the binder if the RASi is stopped

  • HD patients: binders can reduce interdialytic hyperkalaemia (1B)

  • Check K⁺ weekly for the first month, then monthly. Recheck a week after stopping (rebound)

  • Health Canada labels: SZC — hyperkalaemia in adults; 10 g TID for up to 48 h if K⁺ >5.0, maintenance 5–10 g daily (max 10 g); on HD 5 g on non-dialysis days (up to 15 g); not for life-threatening hyperkalaemia on its own. Patiromer — hyperkalaemia in CKD with eGFR ≥15; 8.4 g daily, ±8.4 g at ≥1-week intervals, max 25.2 g

  • UKKA’s 72-h SZC course runs past the Canadian label (48 h)

  • Ontario: SZC and patiromer are not listed on the ODB formulary → private insurance or out of pocket


key points

  • Choice: SZC for speed and acute use; patiromer when sodium load matters (no Na⁺) but its slow onset excludes it as the main acute agent
  • Patiromer binds other oral drugs → give others ≥3 h before or after. SZC transiently raises gastric pH → separate drugs with pH-dependent absorption by 2 h
  • SZC raises bicarbonate (binds NH₄⁺) and doesn’t touch Mg²⁺. Patiromer can lower Mg²⁺
  • Binders don’t replace calcium, insulin-glucose or dialysis in the emergency → potassium disorders
  • Fix constipation (reduces colonic K⁺ excretion), acidosis and glycaemia first in chronic hyperkalaemia
SPS (Kayexalate)

Uncertain efficacy and reports of colonic/intestinal necrosis, especially with sorbitol and in ileus, post-op bowel or transplant patients. UKKA: no role in the acute setting.


adverse effects

  • SZC: oedema (5.7%) and HF/BP worsening from sodium load (~400 mg Na⁺ per 5 g); hypokalaemia (4.1%)
  • Patiromer: hypomagnesaemia, constipation, hypokalaemia; contains sorbitol (avoid in hereditary fructose intolerance). Not studied in bowel obstruction, major GI surgery or severe GI disease (≈50% <4.0 in PEARL-HF at higher doses)
  • SPS/calcium resonium: GI necrosis, constipation, sodium (SPS) or calcium load

evidence

  • OPAL-HK (patiromer, CKD on RASi): 76% reached target K⁺ at 4 weeks. On randomised withdrawal, K⁺ ≥5.5 recurred in 60% (placebo) vs 15% (continued patiromer), and 52% vs 5% had to stop RASi
  • ZS-005 (SZC, 12 months): maintained normokalaemia; monitoring scheme above

Prepared 2026-10-27. Not yet verified — check every number against the sources.

Key references

  • guideline
    Alfonzo A, et al. UK Kidney Association Clinical Practice Guideline: Treatment of Acute Hyperkalaemia in Adults. October 2023.
+4 more sources

Suggest a correction potassium binders